# Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

> **NCT06046248** · PHASE2 · RECRUITING · sponsor: **Northside Hospital, Inc.** · enrollment: 25 (estimated)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** Belumosudil
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06046248
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06046248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06046248, "Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06046248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*